Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.02.2017 | Case report

Gemcitabine

Thrombotic microangiopathy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Hofmann JC, et al. Use of a rapid genetic assay to confirm the diagnosis of complement-mediated thrombotic microangiopathy: A preliminary report. Journal of Clinical Apheresis 30: 66-67, No. 2, Apr 2015. Available from: URL: http://doi.org/10.1002/jca.21385 [abstract] - USA Hofmann JC, et al. Use of a rapid genetic assay to confirm the diagnosis of complement-mediated thrombotic microangiopathy: A preliminary report. Journal of Clinical Apheresis 30: 66-67, No. 2, Apr 2015. Available from: URL: http://​doi.​org/​10.​1002/​jca.​21385 [abstract] - USA
Metadaten
Titel
Gemcitabine
Thrombotic microangiopathy: case report
Publikationsdatum
01.02.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-26729-8

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Interleukin-7

Case report

Levofloxacin